A new approach to drug design can deliver medicine directly to the gut in mice at significantly lower doses than current inflammatory bowel disease treatments.
The proof-of-concept study, published today in Science, introduced a mechanism called ‘GlycoCaging’ that releases medicine exclusively to the lower gut at doses up to 10 times lower than current therapies.
“With this technique, we have the ability to deliver not just steroids, but a range of drugs including anti-microbial compounds…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply